Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage

RecruitingOBSERVATIONAL
Enrollment

260

Participants

Timeline

Start Date

January 11, 2024

Primary Completion Date

March 28, 2024

Study Completion Date

May 31, 2024

Conditions
Gastric Cancer
Interventions
DRUG

Oxaliplatin and capecitabine/ S-1 and capecitabine

Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA\<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA\>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1

Trial Locations (1)

450001

RECRUITING

Department of Gastrointestinal Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER